Literature DB >> 30797781

Evaluation of a 3D Human Artificial Lymph Node as Test Model for the Assessment of Immunogenicity of Protein Aggregates.

Teresa Kraus1, Annika Lubitz2, Ulrike Schließer2, Christoph Giese2, Jana Reuschel2, René Brecht2, Julia Engert3, Gerhard Winter3.   

Abstract

The immunogenicity of protein aggregates has been investigated in numerous studies. Nevertheless, it is still unknown which kind of protein aggregates enhance immunogenicity the most. The ability of the currently used in vitro and in vivo systems regarding their predictability of immunogenicity in humans is often questionable, and results are partially contradictive. In this study, we used a 2D in vitro assay and a complex 3D human artificial lymph node model to predict the immunogenicity of protein aggregates of bevacizumab and adalimumab. The monoclonal antibodies were exposed to different stress conditions such as light, heat, and mechanical stress to trigger the formation of protein aggregates and particles, and samples were analyzed thoroughly. Cells and culture supernatants were harvested and analyzed for dendritic cell marker and cytokines. Our study in the artificial lymph node model revealed that bevacizumab after exposure to heat triggered a TH1- and proinflammatory immune response, whereas no trend of immune responses was seen for adalimumab after exposure to different stress conditions. The human artificial lymph node model represents a new test model for testing the immunogenicity of protein aggregates combining the relevance of a 3D human system with the rather easy handling of an in vitro setup.
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  immunogenicity; immunology; in vitro models; protein aggregation; protein(s)

Year:  2019        PMID: 30797781     DOI: 10.1016/j.xphs.2019.02.011

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Modeling Immunity In Vitro: Slices, Chips, and Engineered Tissues.

Authors:  Jennifer H Hammel; Sophie R Cook; Maura C Belanger; Jennifer M Munson; Rebecca R Pompano
Journal:  Annu Rev Biomed Eng       Date:  2021-04-19       Impact factor: 11.324

Review 2.  Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Nicole L Jarvi; Sathy V Balu-Iyer
Journal:  BioDrugs       Date:  2021-02-01       Impact factor: 5.807

3.  Ectopic Lymphoid Follicle Formation and Human Seasonal Influenza Vaccination Responses Recapitulated in an Organ-on-a-Chip.

Authors:  Girija Goyal; Pranav Prabhala; Gautam Mahajan; Bruce Bausk; Tal Gilboa; Liangxia Xie; Yunhao Zhai; Roey Lazarovits; Adam Mansour; Min Sun Kim; Aditya Patil; Danielle Curran; Jaclyn M Long; Sanjay Sharma; Abidemi Junaid; Limor Cohen; Thomas C Ferrante; Oren Levy; Rachelle Prantil-Baun; David R Walt; Donald E Ingber
Journal:  Adv Sci (Weinh)       Date:  2022-03-14       Impact factor: 17.521

4.  Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.

Authors:  Michael D Swanson; Shantel Rios; Sarita Mittal; George Soder; Vibha Jawa
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

5.  T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.

Authors:  Vibha Jawa; Frances Terry; Jochem Gokemeijer; Shibani Mitra-Kaushik; Brian J Roberts; Sophie Tourdot; Anne S De Groot
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.